US Food and Drug Administration officials wonder whether the 20-point increase in complete response rate shown by Merck & Co. Inc.'s Keytruda in a high-risk bladder cancer is clinically meaningful given the product's safety profile.
Merck has proposed Keytruda (pembrolizumab) for treatment of adults with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with...





